Latest OncoGenex Pharmaceuticals Inc. Stories
BOTHELL, WA and VANCOUVER, BC, Aug. 10, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Michelle Burris, OncoGenex' Executive Vice President of Operations and Chief Financial Officer, will be presenting at the 2011 Wedbush Securities Life Sciences Management Access Conference. The OncoGenex corporate presentation will take place on Wednesday, August 17(th) at 3:35pm ET at Le Parker Meridien Hotel in New York City. The live...
BOTHELL, Wash. and VANCOUVER, Aug. 4, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided an update on current events and activities and announced its second quarter financial results. Second Quarter 2011 Highlights Expected timing of results from the survival primary endpoint for the custirsen SYNERGY Phase 3 clinical trial remains unchanged at Q4 2013. During discussions regarding the SATURN Special Protocol Assessment, or SPA, amendment, FDA stated that an...
BOTHELL, WA and VANCOUVER, July 28, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's second quarter 2011 financial results will be released on Thursday, August 4, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business....
BOTHELL, WA and VANCOUVER, British Columbia, June 28, 2011 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients, announced today that the Company was added to the Russell Global Index, Russell 2000® Index, Russell 3000® Index and Russell Microcap® Index at the close of market on June 24, 2011 as part of the...
BOTHELL, Wash. and VANCOUVER, British Columbia, June 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced new data showing how the company's lead investigational compound, custirsen (OGX-011/TV-1011), may work with innovative therapies MDV3100 and heat-shock protein 90 (Hsp90) inhibitors to suppress prostate cancer cell survival and improve treatment outcomes. These pre-clinical data were presented at the 47th Annual Meeting of the American Society of Clinical...
BOTHELL, WA, and VANCOUVER, May 17 /PRNewswire/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Cameron Lawrence, OncoGenex' Director of Finance and Principal Accounting Officer, will be presenting at the UBS Global Specialty Pharmaceuticals Conference on Wednesday, May 25 at 10:00 a.m. BST (5:00 a.m. ET). The conference takes place at the UBS offices in London. The live audio webcast can be accessed through the Investor Relations page of the OncoGenex...
BOTHELL, WA and VANCOUVER, BC, May 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced its first quarter financial results and provided an update on current events and activities. Key OncoGenex Activities -- Currently enrolling the Phase 3 clinical trial referred to as SYNERGY, to be conducted in approximately 123 cancer centers to evaluate a survival benefit for custirsen in combination with...
BOTHELL, WA and VANCOUVER, May 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced that the Company's first quarter 2011 financial results will be released on Monday, May 9, 2011 after the NASDAQ Global Market closes at 4:00 p.m. ET, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will discuss the company's financial results and provide an update on the business. To access the webcast,...
BOTHELL, Wash. and VANCOUVER, British Columbia, April 14, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the European Patent Office (EPO) has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers." The patent, licensed from The University of British Columbia, includes coverage for antisense and siRNA compositions that reduce the amount of active Heat Shock Protein 27 (Hsp27) in Hsp27...
BOTHELL, Wash. and VANCOUVER, British Columbia, April 4, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that preclinical data utilizing their pipeline compound OGX-427 was presented at the AACR 102nd Annual Meeting 2011. The study demonstrated the ability of OGX-427 to inhibit Heat Shock Protein 27 (Hsp27), a cell-survival protein believed to play an important role in the proliferation of castrate resistant prostate cancer (CRPC) and resistance to...
